Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCILLA: Maintenance strategies for ulcerative colitis remission after infliximab
2016-002707-25Phase 4Completed
- Sponsor
- Humanitas Research Hospital
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of infliximab in autoimmune colitis (2 arms), sponsored by Humanitas Research Hospital. Primary endpoint: Relapse rate at 12 months. Started Jan 2021; status: completed.
02
Drugs
infliximab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2016-002707-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002707-25.